NanoViricides is a developmental
stage company utilizing powerful proprietary nanomedicine technology to target
commercially significant viral diseases. Currently, the company’s primary
programs include drug candidates to treat influenza, external eye viral
diseases, HIV/AIDS, Oral and Genital Herpes and dengue viruses. Thus far, the
company’s anti-viral medicines, which it refers to as NanoViricides®, have
demonstrated very high levels of effectiveness when compared to currently
available methods of treatment.
The company’s drug candidates
are unique in the way that they combat dangerous viral illnesses.
NanoViricides® work by fooling the virus to which they attach in a method
that’s similar to the way that the virus itself attaches to the receptors of
surface cells. This allows the medication to surround and trap the virus,
potentially eliminating the coat proteins needed to bind to cells and
effectively neutralizing the virus without affecting the subject’s immune
system. This proprietary design counteracts the mutations that viruses use to
render currently available antibodies and vaccines ineffective.
Currently, NanoViricides is
conducting investigational new drug (IND) enabling studies on its Injectable
FluCide™ Clinical Candidate, which is the last major step before clinical drug
trials can begin. According to a recent press release, the company estimates
that it has sufficient funding to perform initial clinical studies on at least
one of its primary drug candidates, as well as to bring at least one other drug
candidate into the IND enabling studies stage. This should put the company in a
strong position to demonstrate the effectiveness of its drug platform prior to
the need to seek additional funding moving forward.
In recent years, the overuse of
antibiotics has caught headlines, highlighting the distinct ability of germs to
outsmart today’s drugs. The same is true for viruses, such as influenza, for
which annual vaccines are common. According to the Center for Disease Control,
though these treatment options can be helpful, in many cases, mutated strains
of the virus still run rampant through communities, showing the crippling
limitations of these prevention options. NanoViricides could be on the cusp of
eliminating these limitations with its drug candidates. Since the binding site
of a virus does not significantly change when it mutates, the company’s drug
technologies could, potentially, remain effective despite modifications to
viruses’ cellular makeups.
NanoViricides demonstrated the
immense potential value of its platform recently by rapidly designing a new
drug candidate to combat the Ebola epidemic. In just four months, the company
was able to synthesize a broad-spectrum drug candidate that has been shown to
maintain its effectiveness, even against mutations of the virus in the field.
Though the recent Ebola outbreak is now waning, the epidemic has demonstrated a
serious need for a therapeutic to control any further outbreaks. As the company
continues to use its drug platform to address the needs of the medical
community, near-limitless growth could be on the horizon.
With the company’s Injectable
FluCide™ candidate recently being highlighted as a ‘Top Ten Infectious Diseases
Project to Watch’ by a panel of experts assembled by Informa and the publishers
of In Vivo, Startup and The Pink Sheet, it’s clear that the industry is
beginning to take notice of the immense possibilities of the company’s
proprietary NanoViricides® technology. As it approaches clinical trials for its
leading drug candidate, look for NanoViricides to make strides towards
significant growth in the competitive medical market.
For more information, visit
www.nanoviricides.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
